- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
A substance used for its actions on the gastrointestinal system, including enhancing digestion, reducing gastric acidity, and regulating gastrointestinal motility and water flow. The digestive system's organs, such as the liver, biliary tract, and pancreas, as well as disorders that may impact those organs, are cared for and treated with the aid of medications for the gastrointestinal system.
The functions of medications that influence the gastrointestinal system are the subject of gastrointestinal (GI) pharmacology. These medications restore GI tract function to normal.
Proton pump inhibitors that require a prescription. Esomeprazole (Nexium), lansoprazole (Peracid), omeprazole (Prilosec), pantoprazole (Protonix), rabeprazole (Aciphex), and DE lansoprazole are a few of these (Dexilant) H-2 blockers that require a prescription.
The Global Prescription Gastrointestinal Drugs market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Vedolizumab, a medication for the digestive system, is now available in India thanks to the Japanese pharmaceutical company Takeda. Vedolizumab, a popular biologic medication, will soon be available in India as a part of Takeda India's gastrointestinal (GI) portfolio.
Takeda India is a subsidiary of the renowned Japanese pharmaceutical company Takeda Pharmaceutical Corporation. After hematology, genetic diseases, and immunology, gastrointestinal (GI) disorders are Takeda's second therapeutic focus in India.
Vedolizumab, which will be marketed as Kynteles in India, is used to treat chronic inflammatory bowel illnesses (IBD) such Ulcerative Colitis and Crohn's Disease. According to the manufacturer, patients with moderate to severe inflammatory bowel disease responded favorably to Kennels' safety and efficacy outcomes (IBD).
Although the corporation withheld the pricing, it said that it will be set in accordance with the accessibility and affordability of the Indian market.
The top-notch R&D team at Takeda is passionate and unwaveringly committed to creating ground-breaking treatments. They work together in the areas where patients have the greatest needs, establishing alliances that will allow them to have a bigger impact on patients' lives both now and in the future.
Takeda is advancing clinical care and scientific research in collaboration with other parties, including researchers, patient organizations, and will keep looking for improved ways to treat people with GI and liver illnesses.
| Sl no | Topic |
| 1 | Market Segmentation |
| 2 | Scope of the report |
| 3 | Abbreviations |
| 4 | Research Methodology |
| 5 | Executive Summary |
| 6 | Introduction |
| 7 | Insights from Industry stakeholders |
| 8 | Cost breakdown of Product by sub-components and average profit margin |
| 9 | Disruptive innovation in the Industry |
| 10 | Technology trends in the Industry |
| 11 | Consumer trends in the industry |
| 12 | Recent Production Milestones |
| 13 | Component Manufacturing in US, EU and China |
| 14 | COVID-19 impact on overall market |
| 15 | COVID-19 impact on Production of components |
| 16 | COVID-19 impact on Point of sale |
| 17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
| 18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
| 19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
| 20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
| 21 | Product installation rate by OEM, 2023 |
| 22 | Incline/Decline in Average B-2-B selling price in past 5 years |
| 23 | Competition from substitute products |
| 24 | Gross margin and average profitability of suppliers |
| 25 | New product development in past 12 months |
| 26 | M&A in past 12 months |
| 27 | Growth strategy of leading players |
| 28 | Market share of vendors, 2023 |
| 29 | Company Profiles |
| 30 | Unmet needs and opportunity for new suppliers |
| 31 | Conclusion |
| 32 | Appendix |
© 2017-2025 Mobility Foresights Pvt Ltd. All rights reserved.